(Reuters, UK)-British regulators said on Thursday that they have confirmed 30 rare blood clot incidents after the use of AstraZeneca’s COVID-19 vaccine, 25 more than the agency previously reported.
The Drugs and Healthcare Products Regulatory Agency stated that after using the vaccines produced by BioNTech SE and Pfizer Inc., it has not received such reports of blood clotting events.
Health officials said they still believe that the benefits of this vaccine in preventing COVID-1
Some countries are restricting the use of the AstraZeneca vaccine, while others continue to vaccinate because investigations into reports of rare and sometimes severe blood clots continue.
On March 18, the British Drug Regulatory Agency stated that among 11 million vaccine injections, there were 5 rare cases of cerebral blood clots.
On Thursday, out of a total of 18.1 million doses, 22 cases reported cerebral venous sinus thrombosis, an extremely rare cerebral coagulation disease, and 8 cases reported other coagulation events related to low platelets.
Reporting by Peter Henderson and Julie Steenhuysen; Editing by Chris Reese and Daniel Wallis